Nurix Therapeutics
NRIX
Market cap $948M

12.44 USD

-0.23

1.82%

At close Jul 11, 4:00 PM EDT

After hours

12.48

+0.04

0.32%

1 day

-1.82%

5 days

0.65%

1 month

-1.50%

3 months

36.11%

6 months

-34.56%

Year to date

-36.24%

1 year

-43.53%

5 years

-34.56%

10 years

-34.56%

About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Employees: 286

Healthcare Biotechnology

Funds holding %

of 7,312 funds

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

709% more call options, than puts

Call options by funds: $777K | Put options by funds: $96K

27% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 51

9% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 32

3% less funds holding

Funds holding: 175 [Q4 2024] → 170 (-5) [Q1 2025]

3.03% less ownership

Funds ownership: 114.49% [Q4 2024] → 111.46% (-3.03%) [Q1 2025]

34% less capital invested

Capital invested by funds: $1.53B [Q4 2024] → $1B (-$523M) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

109%

upside

Avg. target

$28

127%

upside

High target

$30

141%

upside

4 analyst ratings

4 positive

100%

0 neutral

0 negative

UBS David Dai	109%upside $26	Buy Maintained	10 Jul 2025
Oppenheimer Matthew Biegler	141%upside $30	Outperform Maintained	10 Jul 2025
Stephens & Co. Sudan Loganathan	141%upside $30	Overweight Reiterated	10 Jul 2025
Needham Gil Blum	117%upside $27	Buy Reiterated	29 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about NRIX published over the past 30 days

Neutral

GlobeNewsWire

2 days ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM)

Neutral

GlobeNewsWire

4 days ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to bexobrutideg (NX-5948) for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Bruton's tyrosine kinase (BTK) which is being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia (WM).

Positive

Zacks Investment Research

1 week ago

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Positive

Zacks Investment Research

1 week ago

Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Neutral

GlobeNewsWire

4 weeks ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Neutral

GlobeNewsWire

4 weeks ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$